Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print October 25, 2006, doi:10.1212/01.wnl.0000247741.72466.8c)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
01.wnl.0000247741.72466.8cv1
67/12/2256    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perrot, X.
Right arrow Articles by Vukusic, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perrot, X.
Right arrow Articles by Vukusic, S.
Received April 24, 2006
Accepted September 5, 2006

Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment

X. Perrot MD*, N. Bernard PharmD, C. Vial MD, J. C. Antoine MD, PhD, H. Laurent MD, T. Vial MD, C. Confavreux MD, PhD, and S. Vukusic MD, PhD

From the Department of Neurology A (X.P., C.C., S.V.) and Department of Electromyography and Muscular Disorders (C.V.), Hôpital Neurologique, and Regional Pharmacovigilance Center (N.B., T.V.), Hospices Civils de Lyon; Department of Neurology (J.C.A.), Hôpital de Bellevue, Saint-Étienne; and Department of Internal Medicine (H.L.), Centre Hospitalier du Pays de Gier, Saint-Chamond, France.


* To whom correspondence should be addressed. E-mail: xavier.perrot{at}chu-lyon.fr.

Abstract-- Telithromycin, a new ketolide antibiotic, has been implicated in the exacerbation or unmasking of myasthenia gravis. This retrospective study presents two clinical reports and summarizes eight other suspected cases notified to the French pharmacovigilance system, highlighting a potentially life-threatening risk of telithromycin treatment in myasthenic patients. An important common feature was that, in seven cases, symptomatology occurred within 2 hours of first telithromycin intake--notably in cases of severe exacerbation.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by AAN Enterprises, Inc.